MedTech Terms
    The authoritative reference
    All terms
    Investment & FinanceStartup Lifecycle

    Royalty Financing

    Non-dilutive capital exchanged for a royalty (typically a percentage of revenue) on a defined product or product family, usually with a capped multiple of invested capital.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 9, 2026

    Definition

    Royalty financing provides upfront capital in exchange for a contractual royalty stream — typically a percentage of net product revenue — until a defined cap (commonly 1.5-3x the financed amount) is reached. In MedTech and the adjacent life-sciences market, dedicated royalty funds (Royalty Pharma, HealthCare Royalty Partners, XOMA) underwrite these structures against products with established revenue or imminent launch. The structure is non-dilutive and typically has no equity, board, or governance rights.

    What this means in practice

    Royalty financing is increasingly used by MedTech companies as bridge capital between approval and profitability, or as a partial monetization of a non-core product line. Cost of capital is generally 12-18% IRR equivalent — cheaper than equity but more expensive than venture debt.
    Common pitfalls
    • •Stacking royalty financing on top of venture debt without modeling combined cash impact at low-revenue scenarios.
    • •Underestimating reporting and audit obligations to the royalty financier.

    Primary references

    3 sources
    Link health: 2 verified 1 bot-blocked· last checked 2026-05-09
    BIO·1SEC EDGAR·1PitchBook·1
    1. 1
      BIO — Non-Dilutive Funding Resources
      Verified
      BIObio.org
    2. 2
      SEC EDGAR — Royalty Pharma 10-K filings
      Verified
      SEC EDGARsec.gov
    3. 3
      PitchBook - MedTech Coverage
      Bot-blocked
      PitchBookpitchbook.com

    Inline markers like [1] jump to the matching reference above.